
22/05/2024
We have signed a definitive agreement to acquire life science company Mirus Bio for US$ 600 million. Mirus Bio is a specialist in the development and commercialization of transfection reagents. These reagents play a key role in the production of viral vectors for cell and gene therapies. The acquisition will advance our integrated offering for viral vector manufacturing and complements the existing portfolio for development and production of novel modalities – a key growth area for our Life Science business sector. More: https://www.emdgroup.com/en/news/definite-agreement-mirus-bio-22-05-2024.html